HomeAI · summaries
Storia in 8 fonti
AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction
The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with ATTR-CM has sent the companies' shares tumbling, while those of their competitors are soaring. The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent cardiovascular events through 140 weeks.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
AstraZeneca, Ionis drug fails big heart disease study in major setback
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and…
- ·
cnbc.com
AstraZeneca stock dives 9% after heart drug trial misses target
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
- ·
endpoints.news
AstraZeneca sinks on unexpected heart drug trial failure
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.
- ·
economictimes.indiatimes.com
AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial
AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua showed no effect in patients already on stabilizer…
- ·
statnews.com
AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.
- ·
benzinga.com
Why Is Ionis Pharmaceuticals, AstraZeneca Stock Tumbling Today? - AstraZeneca (NYSE:AZN), Ionis Pharmaceu
Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary measures and safety remained favorable.
- ·
irishtimes.com
AstraZeneca shares slide 9% after heart treatment disappoints in trial
UK pharmaceutical company said Wainua drug did not meet goal of reducing cardiovascular deaths
- ·
fiercepharma.com
AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction
The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with ATTR-CM…
- ·
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain - Ionis Pharmaceuticals (NASDAQ:IONS)
Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.